Evidence map›Paper›PMID 31145995›Full record

ReviewSeminars in cell & developmental biology2020

From old to new - Repurposing drugs to target mitochondrial energy metabolism in cancer.

Sepideh Aminzadeh-Gohari, Daniela D Weber, Silvia Vidali, Luca Catalano, Barbara Kofler, René G Feichtinger

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cell & developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Drug Repurposing by Tumor Tissue Editing.Frontiers in oncology · 2022
    Review
  10. Review
  11. The Contextual Essentiality of Mitochondrial Genes in Cancer.Frontiers in cell and developmental biology · 2021
    Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sepideh Aminzadeh-GohariResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Daniela D WeberResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Silvia VidaliResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria; Institute of Human Genetics, Helmholtz Zentrum München, Technical University of Munich, Munich, Germany.
Luca CatalanoResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Barbara KoflerResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria. Electronic address: b.kofler@salk.at.
René G FeichtingerResearch Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Paracelsus Medical University · ATHelmholtz Zentrum München · DE

Funding

Austrian Science Fund FWF P 31228
6 · The paper itself

Abstract

Although we have entered the era of personalized medicine and tailored therapies, drugs that target a large variety of cancers regardless of individual patient differences would be a major advance nonetheless. This review article summarizes current concepts and therapeutic opportunities in the area of targeting aerobic mitochondrial energy metabolism in cancer. Old drugs previously used for diseases other than cancer, such as antibiotics and antidiabetics, have the potential to inhibit the growth of various tumor entities. Many drugs are reported to influence mitochondrial metabolism. However, here we consider only those drugs which predominantly inhibit oxidative phosphorylation.

Indexed as

AnimalsAntineoplastic AgentsDrug RepositioningEnergy MetabolismHumansMitochondriaNeoplasmsAntineoplastic AgentsAerobic mitochondrial energy metabolismAntibioticAntidiabeticChemotherapeuticOxidative phosphorylation complex

Identifiers

PMID31145995
PMCPMC7613924
OpenAlexW2948076469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.